Scancell Holdings plc (FRA:SCP)
Germany
· Delayed Price · Currency is EUR 0.0765
0.00 (0.00%)
At close: Dec 5, 2025
Scancell Holdings Revenue
In the fiscal year ending April 30, 2025, Scancell Holdings had annual revenue of 4.71M GBP. Scancell Holdings had revenue of 4.71M in the half year ending April 30, 2025.
Revenue
4.71M GBP
Revenue Growth
n/a
P/S Ratio
21.36
Revenue / Employee
78.52K GBP
Employees
60
Market Cap
118.26M EUR
Revenue Chart
* This company reports financials in GBP.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Rheinmetall AG | 11.00B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
Scancell Holdings News
- 3 months ago - Scancell Holdings Plc (SCNLF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025 - GlobeNewsWire
- 4 months ago - Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ - GlobeNewsWire
- 1 year ago - PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma - Business Wire
- 2 years ago - PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free - Business Wire